How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

746 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Ultrasound Assessment of the Carotid Intimal Medial Thickness in Obese Subjects; Weight Loss

programme (or within the last 3 months) Current or history of treatment with medications that may cause significant weight gain for at least 3 months before this trial Current use or use within three months before this trial of GLP-1 receptor agonist, pramlintide, sibutramine, orlistat, zonisamide, topiramate, or phentermine Type 1 diabetes Type 2 diabetes treated with glucose-lowering drugs other than metformin Alloplasty in target knee joint (see section 6.3) End stage disease in target knee joint

2016 Clinical Trials

142. Liraglutide 3 mg for Knee Osteoarthritis

, in an organised weight loss programme (or within the last 3 months) Current or history of treatment with medications that may cause significant weight gain for at least 3 months before this trial Current use or use within three months before this trial of GLP-1 receptor agonist, pramlintide, sibutramine, orlistat, zonisamide, topiramate, or phentermine Type 1 diabetes Type 2 diabetes treated with glucose-lowering drugs other than metformin Alloplasty in target knee joint (see section 6.3) End stage disease

2016 Clinical Trials

143. Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance

the last 3 months) Current or history of treatment with medications that may cause significant weight gain for at least 3 months before this trial Current use or use within three months before this trial of GLP-1 receptor agonist, pramlintide, sibutramine, orlistat, zonisamide, topiramate, or phentermine Type 1 diabetes Type 2 diabetes treated with glucose-lowering drugs other than metformin Alloplasty in target knee joint (see section 6.3) End stage disease in target knee joint (Kellgren-Lawrence

2016 Clinical Trials

144. Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Loss

programme (or within the last 3 months) Current or history of treatment with medications that may cause significant weight gain for at least 3 months before this trial Current use or use within three months before this trial of GLP-1 receptor agonist, pramlintide, sibutramine, orlistat, zonisamide, topiramate, or phentermine Type 1 diabetes Type 2 diabetes treated with glucose-lowering drugs other than metformin Alloplasty in target knee joint (see section 6.3) End stage disease in target knee joint

2016 Clinical Trials

145. The Assessment of the Effect of Vitamin D Supplementation on Inflammatory and Endothelial Factors in the Patients With Type 2 Diabetes .

- or hyperthyroidism, treatment with orlistat or sibutramine for weight loss, pregnancy and lactation, treatment with insulin or Thiazolidinediones, Smokers,sever change in regular diet and life style,change in type and dosage of regular medication (s) Contacts and Locations Go to No Contacts or Locations Provided More Information Go to Layout table for additonal information Responsible Party: Tehran University of Medical Sciences ClinicalTrials.gov Identifier: Other Study ID Numbers: 32615 First Posted: January 2

2016 Clinical Trials

146. Drug interventions for the treatment of obesity in children and adolescents. (PubMed)

), sibutramine (six trials), orlistat (four trials), and one trial arm investigated the combination of metformin and fluoxetine. The ongoing trials evaluated metformin (four trials), topiramate (two trials) and exenatide (two trials). A total of 2484 people participated in the included trials, 1478 participants were randomised to drug intervention and 904 to comparator groups (91 participants took part in two cross-over trials; 11 participants not specified). Eighteen trials used a placebo in the comparator (...) split by drug type, sibutramine, metformin and orlistat all showed reductions in BMI in favour of the intervention.Intervention versus comparator for change in weight showed a MD of -3.9 kg (95% CI -5.9 to -1.9; P < 0.00001; 11 trials; 1180 participants; low certainty evidence). As with BMI, when the trials were split by drug type, sibutramine, metformin and orlistat all showed reductions in weight in favour of the intervention.Five trials reported serious adverse events: 24/878 (2.7%) participants

Full Text available with Trip Pro

2016 The Cochrane database of systematic reviews

147. Evolution of Pharmacological Obesity Treatments: Focus on Adverse Side-Effect Profiles. (PubMed)

(PPA)], excess non-fatal cardiovascular events (sibutramine), and neuro-psychiatric issues (rimonabant; approved in Europe, but not in the USA). This negative experience has helped mould the current drug development and approval process for new anti-obesity drugs. Differences between the US Food and Drug Administration (FDA) and the European Medicines Agency, however, in perceptions of risk-benefit considerations for individual drugs have resulted in discrepancies in approval and/or withdrawal

2016 obesity & metabolism

148. Preparation of a β-Cyclodextrin-Based Open-Tubular Capillary Electrochromatography Column and Application for Enantioseparations of Ten Basic Drugs (PubMed)

concentration and background electrolyte pH on the chiral separation were investigated. With the developed separation mode, all the enantiomers (except for venlafaxine) were baseline separated in resolutions of 4.49, 1.68, 1.88, 1.57, 2.52, 2.33, 3.24, 1.63 and 3.90 for zopiclone, chlorphenamine maleate, brompheniramine maleate, dioxopromethazine hydrochloride, carvedilol, homatropine hydrobromide, homatropine methylbromide, venlafaxine, sibutramine hydrochloride and terbutaline sulfate, respectively

Full Text available with Trip Pro

2016 PloS one

149. Catgut Implantation at Acupoints for the Treatment of Simple Obesity

interventions in controlled trials of acupuncture: the STRICTA recommendations. J Altern Complement Med. 2002;8:85 - 9. Ralph JL, Von Ah D, Scheett AJ, Hoverson BS, Anderson CM. Diet assessment methods: a guide for oncology nurses. Clin J Oncol Nurs. 2011;15:E114 - 21. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance Lancet

2016 Clinical Trials

150. A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome. (PubMed)

(in men only). Meta-analysis of three studies showed a robust effect of metformin in reducing body mass index and waist circumference but no effects on blood glucose, triglyceride levels, or HDL levels. In addition, there is limited evidence for combined calorie restriction and exercise as a non-pharmacological alternative for the treatment of clozapine-induced obesity, but only in an in-patient setting. Rosiglitazone, topiramate, sibutramine, phenylpropanolamine, modafinil, and atomoxetine have

Full Text available with Trip Pro

2016 European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

151. [Acupuncture for treatment of simple obesity and its effect on serum leptin level of the patient]. (PubMed)

(Shenmen, Endocrine, etc. were selected); the patients in the control group were treated with oral administration of sibutramine. The serum leptin level before and after treatment were determined and the therapeutic effect in reducing body weight was assessed.The total effective rate was 88.0% in the acupuncture group and 80. 0% in the control group, with no significant difference between the two groups (P>0.05); after treatment, the serum leptin level in both the two groups decreased significantly (P

2016 Zhongguo zhen jiu = Chinese acupuncture & moxibustion Controlled trial quality: uncertain

152. Relation between weight loss and causes of death in patients with cardiovascular disease: finding from the SCOUT trial. (PubMed)

Relation between weight loss and causes of death in patients with cardiovascular disease: finding from the SCOUT trial. Obesity is associated with an increased incidence of mortality. The Sibutramine Cardiovascular Outcomes (SCOUT) trial can provide the first evidence of the effect of intentional weight loss on mortality in an obese population at high risk.SCOUT was a randomized, double-blind, placebo-controlled trial testing sibutramine vs. placebo. Eligibility for the trial required both men (...) event.The relationship between weight loss and mortality (all-cause, cardiovascular, and noncardiovascular) was investigated with Cox regression models.The main study showed that all-cause mortality was not different in patients allocated to sibutramine or placebo. This ancillary analysis demonstrates that there is a general trend showing higher mortality in patients with the greatest weight loss (weight reduction >10 kg) and in those with increasing weight (>1 kg). If integrated weight loss (area under

Full Text available with Trip Pro

2016 Journal of cardiovascular medicine (Hagerstown, Md.) Controlled trial quality: predicted high

153. What weight loss treatment options do geriatric patients with overweight and obesity want to consider? (PubMed)

What weight loss treatment options do geriatric patients with overweight and obesity want to consider? Since the 1990s, a number of weight loss medications have been removed from the USA and or European market because of adverse events associated with these medications. These medications include fenfluramine (heart valve thickening), sibutramine (cardiovascular risk) and rimonabant (depression). This history may affect a patient's desire to consider weight loss medications as an option

Full Text available with Trip Pro

2016 Obesity science & practice

154. Management of diabetes

participants with type 2 diabetes, hypertension, MI, asthma and breast cancer. Four RCTs provided data comparing a Protein Sparing Modified Fast (PSMF) with a Low Calorie Diet (LCD) and found no statistically significant differences in HbA1c or weight loss between these two interventions. 107 A systematic review, including 22 studies on pharmacotherapy for weight loss in adults with type 2 diabetes, focused mainly on weight loss and HbA1c data for orlistat (n=2,036 participants), sibutramine (n=296 (...) ) and fluoxetine (n=1,047). 108 Orlistat resulted in a mean pooled effect weight loss of 2.0 kg (95% CI 1.3 to 2.8) associated with a reduction in HbA1c of 0.5% (5.46 mmol/mol) (95% CI 0.3 (3.28) to 0.6 (6.56)) with follow up between 24 and 57 weeks. Sibutramine resulted in mean pooled effect weight loss of 5.1 kg (95% CI 3.2 to 7.0) with no reduction in HbA1c after follow up of 12 to 52 weeks. Fluoxetine resulted in mean pooled effect weight loss of 3.4 kg (95% CI, 1.7 to 5.2) at 8 to 16 weeks, 5.1 kg (95% CI

2010 SIGN

156. Long-term randomized clinical trials of pharmacological treatment of obesity: systematic review

search terms were reported. Study selection Randomised controlled trials that evaluated the efficacy of treatments with orlistat, sibutramine and rimonabant, that followed participants for at least 24 months and that measured weight loss were eligible for inclusion. Participants with hypertension (sibutramine studies) and neuro-psychiatric diseases (rimonabant studies) were excluded. Most studies included clinically obese white women (without cardiac, renal, liver and gastrointestinal illnesses (...) to intervention. Results of the review Eleven RCTs (n=11,710, range 61 to 3,305 participants) met the inclusion criteria. Seven studies assessed orlistat and two studies each assessed sibutramine and rimonabant. One study scored 5, three studies scored 4, five studies scored 3 and one study scored 2 on the Jadad scale (score for one study not reported). Eight studies were double blind. Nine studies were analysed by intention to treat (ITT). Baseline differences were reported to be significant. Withdrawal

2010 DARE.

158. Weight-reducing drugs may be beneficial in hypertensive patients

Weight-reducing drugs may be beneficial in hypertensive patients PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Weight-reducing drugs may be beneficial in hypertensive patients Clinical question How effective are weight-reducing drugs in hypertensive patients? Bottom line Although trials of orlistat and sibutramine in patients with elevated blood pressure demonstrated statistically (...) significant decreases in weight, orlistat reduced blood pressure and sibutramine increased blood pressure. Caveat No long term mortality and morbidity RCT evidence is available for these drugs. Trials of rimonabant in this patient population could not be included. Context Orlistat, sibutramine and rimonabant are the main anti- obesity drugs in current use. Orlistat and sibutramine have been approved for long term treatment of obesity throughout much of the world. Rimonabant was approved for use

2011 Cochrane PEARLS

159. Finally, the Department of Justice and FDA go after unsafe supplements in a big way

manufacturing practices regulations. Truly, this was an example of . Oh, and Bethel also made medical claims that some of their supplements were able to cure, mitigate, treat, or prevent diseases. It turns out that some of the products marketed as dietary supplements by Bethel contained—you guessed it!—real drugs. These included sibutramine, the active ingredient of Meridia, a drug approved in 1997 to treat obesity that was removed from the market in 2010 because of the risk of serious adverse events

2015 Respectful Insolence

160. Interventions for treating obesity in children. (PubMed)

and sibutramine) were found in 10 studies. No surgical intervention was eligible for inclusion. The studies included varied greatly in intervention design, outcome measurements and methodological quality.Meta-analyses indicated a reduction in overweight at 6 and 12 months follow up in: i) lifestyle interventions involving children; and ii) lifestyle interventions in adolescents with or without the addition of orlistat or sibutramine. A range of adverse effects was noted in drug RCTs.While there is limited (...) quality data to recommend one treatment program to be favoured over another, this review shows that combined behavioural lifestyle interventions compared to standard care or self-help can produce a significant and clinically meaningful reduction in overweight in children and adolescents. In obese adolescents, consideration should be given to the use of either orlistat or sibutramine, as an adjunct to lifestyle interventions, although this approach needs to be carefully weighed up against the potential

Full Text available with Trip Pro

2009 Cochrane

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>